Greenwich LifeSciences

GLSIPhase 3

Greenwich LifeSciences is focused on developing breakthrough immunotherapies to prevent breast cancer recurrence, targeting a critical unmet need for millions of survivors. Its lead candidate, GLSI-100 (GP2 + GM-CSF), demonstrated an 80% or greater reduction in recurrence rates in a Phase IIb trial led by MD Anderson. The company is now advancing this candidate through a large, global Phase III trial with a distinguished steering committee and has strong manufacturing readiness with commercial-scale product already produced. Management and board ownership exceeds 50%, aligning strongly with shareholder interests.

Market Cap

$333.9M

Focus

Biologics

GLSI · Stock Price

USD 24.10+3.69 (+18.08%)

Historical price data

AI Company Overview

Technology Platform

Peptide-based cancer immunotherapy platform focused on HER2/neu-derived antigens (like GP2) combined with immune adjuvants (GM-CSF) to stimulate targeted CD8+ T-cell responses for preventing cancer recurrence.

Pipeline Snapshot

1 drug in pipeline, 1 in Phase 3

Drug	Indication	Stage	Watch
Placebo + GLSI-100	Breast Cancer	Phase 3

Opportunities

Significant opportunities exist to expand the market for GLSI-100 beyond the initial HLA-A*02 population, including development for other HLA types.

Further pipeline expansion could involve combinations with CD4/CD8 peptides or checkpoint inhibitors, and application to other HER2/neu expressing cancers (e.g., gastric).

Risk Factors

Key risks include failure of the Phase III trial to meet its high efficacy threshold, regulatory hurdles post-trial, future capital needs potentially causing shareholder dilution, and challenges in commercializing as a single-asset company in a competitive oncology market.

Competitive Landscape

Primary competition comes from established HER2-targeted therapies like Herceptin and Kadcyla, which reduce recurrence by ~50%. GLSI-100 aims to demonstrate superior efficacy (>70% reduction) as an immunotherapy with a different mechanism (T-cell activation) and favorable safety profile, positioning it as a potential breakthrough adjuvant maintenance therapy.